Early short-term hypoxia promotes epidermal cell migration by activating the CCL2-ERK1/2 pathway and epithelial–mesenchymal transition during wound healing

Abstract

Background: Due to vasculature injury and increased oxygen consumption, the early wound microenvironment is typically in a hypoxic state. We observed enhanced cell migration ability under early short-term hypoxia. CCL2 belongs to the CC chemokine family and was found to be increased in early hypoxic wounds and enriched in the extracellular signal-regulated kinase (ERK)1/2 pathway in our previous study. However, the underlying mechanism through which the CCL2-ERK1/2 pathway regulates wound healing under early short-term hypoxia remains unclear. Activation of epithelial–mesenchymal transition (EMT) is a key process in cancer cell metastasis, during which epithelial cells acquire the characteristics of mesenchymal cells and enhance cell motility and migration ability. However, the relationship between epithelial cell migration and EMT under early short-term hypoxia has yet to be explored. Methods: HaCaT cells were cultured to verify the effect of early short-term hypoxia on migration through cell scratch assays. Lentiviruses with silenced or overexpressed CCL2 were used to explore the relationship between CCL2 and migration under short-term hypoxia. An acute full-thickness cutaneous wound rat model was established with the application of an ERK inhibitor to reveal the hidden role of the ERK1/2 pathway in the early stage of wound healing. The EMT process was verified in all the above experiments through western blotting. Results: In our study, we found that short-term hypoxia promoted cell migration. Mechanistically, hypoxia promoted cell migration through mediating CCL2. Overexpression of CCL2 via lentivirus promoted cell migration, while silencing CCL2 via lentivirus inhibited cell migration and the production of related downstream proteins. In addition, we found that CCL2 was enriched in the ERK1/2 pathway, and the application of an ERK inhibitor in vivo and in vitro verified the upstream and downstream relationships between the CCL2 pathway and ERK1/2. Western blot results both in vivo and in vitro demonstrated that early short-term hypoxia promotes epidermal cell migration by activating the CCL2-ERK1/2 pathway and EMT during wound healing. Conclusions: Our work demonstrated that hypoxia in the early stage serves as a stimulus for triggering wound healing through activating the CCL2-ERK1/2 pathway and EMT, which promote epidermal cell migration and accelerate wound closure. These findings provide additional detailed insights into the mechanism of wound healing and new targets for clinical treatment.

Keywords

Hypoxia / Epidermal cells / Wound healing / Epithelial–mesenchymal transition / CCL2 / Extracellular signal-regulated kinase

References

[1] Rodrigues M, Kosaric N, Bonham CA, Gurtner GC. Wound healing: a cellular perspective. Physiol Rev. 2019; 99: 665-706.

[2] Qing C. The molecular biology in wound healing & non-healing wound. Chin J Traumatol. 2017; 20: 189-93.

[3] Mihai MM, Dima MB, Dima B, Holban AM. Nanomaterials for wound healing and infection control. Materials (Basel). 2019; 12: 2176.

[4] Yang J, Liu X, Wang W, Chen Y, Liu J, Zhang Z, et al. Bioelectric fields coordinate wound contraction and re-epithelialization process to accelerate wound healing via promoting myofibroblast transformation. Bioelectrochemistry. 2022; 148: 108247.

[5] Liu X, Yang J, Kong M, Jiang M, Liu L, Zhang J, et al. CD9 negatively regulates collective electrotaxis of the epidermal monolayer by controlling and coordinating the polarization of leader cells. Burns Trauma. 2023; 11: tkad012.

[6] Sparks HD, Mandla S, Vizely K, Rosin N, Radisic M, Biernaskie J. Application of an instructive hydrogel accelerates re-epithelialization of xenografted human skin wounds. Sci Rep. 2022; 12: 14233.

[7] Shi ZY, Zhang BH, Sun JC, Liu XZ, Shen ZA. Research advances on the role and mechanism of epidermal stem cells in skin wound repair. Chin J Burns Wounds. 2022; 09: 854-8.

[8] Fife CE, Carter MJ. Wound care outcomes and associated cost among patients treated in US outpatient wound Centers: data from the US wound registry. Wounds. 2012; 24: 10-7.

[9] Leavitt T, Hu MS, Marshall CD, Barnes LA, Lorenz HP, Longaker MT. Scarless wound healing: finding the right cells and signals. Cell Tissue Res. 2016; 365: 483-93.

[10] Yao L, Rathnakar BH, Kwon HR, Sakashita H, Kim JH, Rackley A, et al. Temporal control of PDGFRα regulates the fibroblast-to-myofibroblast transition in wound healing. Cell Rep. 2022; 40: 111192.

[11] Scopelliti F, Cattani C, Dimartino V, Mirisola C, Cavani A. Platelet derivatives and the immunomodulation of wound healing. Int J Mol Sci. 2022; 23.

[12] Peng Z, Pang H, Wu H, Peng X, Tan Q, Lin S, et al. CCL2 promotes proliferation, migration and angiogenesis through the MAPK/ERK1/2/MMP9, PI3K/AKT, Wnt/β-catenin signaling pathways in HUVECs. Exp Ther Med. 2023; 25: 77.

[13] Jin R, Zhou M, Lin F, Xu W, Xu A. Pathogenic Th2 cytokine profile skewing by IFN-γ-responding vitiligo fibroblasts via CCL2/CCL8. Cells. 2023; 12: 217.

[14] Shi Z, Yu P, Lin WJ, Chen S, Hu X, Chen S, et al. Microglia drive transient insult-induced brain injury by chemotactic recruitment of CD8(+) T lymphocytes. Neuron. 2023; 111: 696-710.e9.

[15] Zhu Z, Guo L, Yeltai N, Xu H, Zhang Y. Chemokine (C-C motif) ligand 2-enhanced adipogenesis and angiogenesis of human adipose-derived stem cell and human umbilical vein endothelial cell co-culture system in adipose tissue engineering. J Tissue Eng Regen Med. 2022; 16: 163-76.

[16] Shen H, Huang X, Zhao Y, Wu D, Xue K, Yao J, et al. The hippo pathway links adipocyte plasticity to adipose tissue fibrosis. Nat Commun. 2022; 13: 6030.

[17] Wang B, Gu X, Xiang BL, Zhao JQ, Zhang CH, Huang PD, et al. eEF-2K knockdown synergizes with STS treatment to inhibit cell proliferation, migration, and invasion via the TG2/ERK pathway in A549 cells. J Biochem Mol Toxicol. 2022; 36: e23158.

[18] Chen T, Wang L, Chen C, Li R, Zhu N, Liu R, et al. HIF-1α-activated TMEM237 promotes hepatocellular carcinoma progression via the NPHP1/Pyk2/ERK pathway. Cell Mol Life Sci. 2023; 80: 120.

[19] Lee JW, Cho JY, Thuy PX, Moon EY. HeLa cervical cancer cells are maintained by Nephronophthisis 3-associated primary cilium formation via ROS-induced ERK and HIF-1α activation under serum-deprived normoxic condition. Int J Mol Sci. 2022; 23: 14500.

[20] Mishra AK, Singh SK, Dayanandan S, Banerjee S, Chakraborty S, Gopal AB, et al. Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: elements of a recipe for disaster. Cytokine. 2022; 156: 155917.

[21] Ren H, Zhao F, Zhang Q, Huang X, Wang Z. Autophagy and skin wound healing. Burns Trauma. 2022; 10: tkac003.

[22] Guo M, Zhang M, Cao X, Fang X, Li K, Qin L, et al. Notch4 mediates vascular remodeling via ERK/JNK/P38 MAPK signaling pathways in hypoxic pulmonary hypertension. Respir Res. 2022; 23: 6.

[23] Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019; 29: 212-26.

[24] Manfioletti G, Fedele M. Epithelial-mesenchymal transition (EMT) 2021. Int J Mol Sci. 2022; 23: 5848.

[25] Liu L, Sun Q, Davis F, Mao J, Zhao H, Ma D. Epithelial-mesenchymal transition in organ fibrosis development: current understanding and treatment strategies. Burns Trauma. 2022; 10: tkac011.

[26] Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development. 2012; 139: 3471-86.

[27] Owusu-Akyaw A, Krishnamoorthy K, Goldsmith LT, Morelli SS. The role of mesenchymal-epithelial transition in endometrial function. Hum Reprod Update. 2019; 25: 114-33.

[28] Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science. 1996; 274: 259-62.

[29] Soutto M, Belkhiri A, Piazuelo MB, Schneider BG, Peng D, Jiang A, et al. Loss of TFF1 is associated with activation of NF-kappaB-mediated inflammation and gastric neoplasia in mice and humans. J Clin Invest. 2011; 121: 1753-67.

[30] Elnagdy MH, Farouk O, Seleem AK, Nada H. A. TFF1 and TFF3 mRNAs are higher in blood from breast cancer patients with metastatic disease than those without. J Oncol. 2018; 2018: 4793498.

[31] Spadazzi C, Mercatali L, Esposito M, We Y, Liverani C, De Vita A. Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis. Bone. 2021; 144: 115775.

[32] Gao S, Wang S, Zhao Z, Zhang C, Liu Z, Ye P. TUBB4A interacts with MYH9 to protect the nucleus during cell migration and promotes prostate cancer via GSK3beta/beta-catenin signalling. Nat Commun. 2022; 13: 2792.

[33] Lee S, Choi E, Chae S, Koh JH, Choi Y, Kim JG. Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profiling. Ann Rheum Dis. 2023; 82: 1035-48.

[34] Ho WT, Chang JS, Chou SF, Hwang WL, Shih PJ, Chang SW. Targeting non-muscle myosin II promotes corneal endothelial migration through regulating lamellipodial dynamics. J Mol Med (Berl). 2019; 97: 1345-57.

[35] Schramek D, Sendoel A, Jeremy P Segal, Slobodan Beronja, Evan Heller, Daniel Oristian, direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science. 2014; 343: 309-13.

[36] Littleflower AB, Antony GR, Parambil ST, Subhadradevi L. Metabolic phenotype intricacies on altered glucose metabolism of breast cancer cells upon Glut-1 inhibition and mimic hypoxia In vitro. Appl Biochem Biotechnol. 2023; 195: 5838-54.

[37] Yang Y, Li Y, Yang Q, Liu Z, Chang X, Yang H. FAT4 activation inhibits epithelial-mesenchymal transition (EMT) by promoting autophagy in H2228/Cer cells. Med Oncol. 2022; 40: 64.

[38] Zhang D, Liu H, Wang W, Gang X, Yin C, Wang S. STEAP2 promotes osteosarcoma progression by inducing epithelial-mesenchymal transition via the PI3K/AKT/mTOR signaling pathway and is regulated by EFEMP2. Cancer Biol Ther. 2022; 23: 1-16.

[39] Rasouli M, Fattahi R, Nuoroozi G, Zarei-Behjani Z, Yaghoobi M, Hajmohammadi Z, et al. The role of oxygen tension in cell fate and regenerative medicine: implications of hypoxia/hyperoxia and free radicals. Cell Tissue Bank. 2024; 25: 195-215.

[40] Guan Y, Niu H, Zhongting Liu Y, Dang JS, Zayed M. Sustained oxygenation accelerates diabetic wound healing by promoting epithelialization and angiogenesis and decreasing inflammation. Sci Adv. 2021; 7: eabj0153.

[41] Shiekh PA, Singh A, Kumar A. Exosome laden oxygen releasing antioxidant and antibacterial cryogel wound dressing OxOBand alleviate diabetic and infectious wound healing. Biomaterials. 2020; 249: 120020.

[42] Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005; 366: 1736-43.

[43] Dissemond J, Kröger K, Storck M, Risse A, Engels P. Topical oxygen wound therapies for chronic wounds: a review. J Wound Care. 2015; 24: 53-63.

[44] Gordillo GM, Sen CK. Revisiting the essential role of oxygen in wound healing. Am J Surg. 2003; 186: 259-63.

[45] Csete M.Oxygen in the cultivation of stem cells. Ann N Y Acad Sci. 2005; 1049: 1-8.

[46] Warren L, Grayson, Feng Zhao, Bruce Bunnell, Teng Ma, hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun. 2007; 358: 948-53.

[47] Samal JRK, Rangasami VK, Samanta S, Varghese OP, Oommen OP. Discrepancies on the role of oxygen gradient and culture condition on mesenchymal stem cell fate. Adv Healthc Mater. 2021; 10: e2002058.

[48] Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation. 2004; 109: 1292-8.

[49] Sadat S, Gehmert S, Song YH, Yen Y, Bai X, Gaiser S, et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun. 2007; 363: 674-9.

[50] Thangarajah H, Vial IN, Chang E, el-Ftesi S, Januszyk M, Chang EI, et al. IFATS collection: adipose stromal cells adopt a proangiogenic phenotype under the influence of hypoxia. Stem Cells. 2009; 27: 266-74.

[51] Mittal V.Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018; 13: 395-412.

[52] Vyas-Read S, Wang W, Kato S, Colvocoresses-Dodds J, Fifadara NH, Gauthier TW, et al. Nimita H Fifadara, Theresa W Gauthie, Hyperoxia induces alveolar epithelial-to-mesenchymal cell transition. Am J Physiol Lung Cell Mol Physiol. 2014; 306: L326-40.

[53] Zhang Q, Han Z, Zhu Y, Chen J, Li W. Role of hypoxia inducible factor-1 in cancer stem cells (review). Mol Med Rep. 2021; 23: 1.

[54] Bosco MC, D’Orazi G, Del Bufalo D. Targeting hypoxia in tumor: a new promising therapeutic strategy. J Exp Clin Cancer Res. 2020; 39: 8.

[55] Jahanban-Esfahlan R, de la Guardia M, Ahmadi D, Yousefi B. Modulating tumor hypoxia by nanomedicine for effective cancer therapy. J Cell Physiol. 2018; 233: 2019-31.

[56] Balamurugan K.HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer. 2016; 138: 1058-66.

[57] Najafi M, Farhood B, Mortezaee K, Kharazinejad E, Majidpoor J, Ahadi R. Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance. J Cancer Res Clin Oncol. 2020; 146: 19-31.

[58] Deng J, Li J, Sarde A, Lines JL, Lee YC, Qian DC. Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Immunol Res. 2019; 7: 1079-90.

[59] Sun YF, Li L, YaWei W, Yang KP. PD-1/PD-L1 in cardiovascular disease. Clin Chim Acta. 2020; 505: 26-30.

[60] Wang J, Zeng H, Zhang H, Han Y. The role of exosomal PD-L1 in tumor immunotherapy. Transl Oncol. 2021; 14: 101047.

[61] Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPalpha immune checkpoint. Immunity. 2020; 52: 742-52.